RE: My Tuppence Worth on Events Since Yesterday29 Feb 2024 12:54
Understanding that the c.24 months cash runway now secured should be sufficient to support planning for introduction of the Group’s first targeted chemotherapy to market before the end of 2026, the Board’s key ambition to retain 100% ownership of its pre|CISION™ platform looks likely to be realised. Subsequent multiple licensing and partnerships deals with international pharmaceutical groups that can be expected to follow this first successful commercialisation, in parallel with Avacta’s own ongoing in-house developments, would dramatically accelerate roll-out of the technology to a broad range of solid tumour candidates, in the process ensuring substantial medium and long-term rewards for shareholders.
Anticipate this share price will triple by this time next year 😉